GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » Return-on-Tangible-Equity

Danaher (Danaher) Return-on-Tangible-Equity : Negative Tangible Equity% (As of Mar. 2024)


View and export this data going back to 1986. Start your Free Trial

What is Danaher Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Danaher's annualized net income for the quarter that ended in Mar. 2024 was $4,352 Mil. Danaher's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $-8,080 Mil. Therefore, Danaher's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was Negative Tangible Equity%.

The historical rank and industry rank for Danaher's Return-on-Tangible-Equity or its related term are showing as below:

DHR' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 697.74   Med: 697.74   Max: 697.74
Current: Negative Tangible Equity

During the past 13 years, Danaher's highest Return-on-Tangible-Equity was 697.74%. The lowest was 697.74%. And the median was 697.74%.

DHR's Return-on-Tangible-Equity is ranked better than
99.51% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: -0.63 vs DHR: Negative Tangible Equity

Danaher Return-on-Tangible-Equity Historical Data

The historical data trend for Danaher's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Danaher Return-on-Tangible-Equity Chart

Danaher Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Danaher Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Competitive Comparison of Danaher's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Danaher's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Danaher's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Danaher's Return-on-Tangible-Equity falls into.



Danaher Return-on-Tangible-Equity Calculation

Danaher's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=4764/( (-7015+-8868 )/ 2 )
=4764/-7941.5
=Negative Tangible Equity %

Danaher's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=4352/( (-8868+-7292)/ 2 )
=4352/-8080
=Negative Tangible Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Danaher  (NYSE:DHR) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Danaher Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Danaher's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Danaher (Danaher) Business Description

Address
2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, USA, 20037-1701
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in two segments--life sciences and diagnostics--after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
Executives
Jose-carlos Gutierrez-ramos officer: SVP, Chief Scientific Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Linda Filler director 2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037
Daniel Raskas officer: VP-Corporate Development 2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006
Teri List director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Joakim Weidemanis officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Walter G Lohr director DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Georgeann Couchara officer: SVP, Human Resources 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Raymond C Stevens director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew officer: EVP & Chief Financial Officer 2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Jennifer Honeycutt officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Alan G Spoon director 1150 15TH ST NW, WASHINGTON DC 20071
Rainer Blair officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Feroz Dewan director C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Mitchell P Rales director, officer: Chairman of Exec. Committee 11790 GLEN ROAD, POTOMAC MD 20854
Brian W Ellis officer: Senior Vice President - GC 2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037

Danaher (Danaher) Headlines

From GuruFocus

Q2 2022 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2020 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024